ArticleDrug safety2020

Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?

Timothé Ménard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.